COVID-19 - Moderna Vaccine set for final trial Stage after effective results.
The US biotech firm confirms that it will enter its third stage of the human trials for COVID-19 Vaccine on the 27th of July.
The third phase will recruit 30,000 participants in the United States, with half of the participants to receive the vaccine at 100mg dose levels. The other half will receive a placebo.
The vaccine is to learn whether the vaccine can prevent the infection or if people still get infected or whether the vaccine can stop infection growing into symptoms.
The US biotech firm mentioned that the vaccine will still be considered a success if it stops severe cases of COVID-19.
This study is to run till October 27th.
This vaccine led patients to produce antibodies that can neutralise the virus. The vaccine caused minor side effects in many patients according to the first published data.
The National Institutes of Health, showed that volunteers who received the vaccine made more neutralising antibodies. The director at the Feinstein Institute for Medical Research, Betty Diamond stated that there are certainly lots of things we don't know yet right now.
Content created and supplied by: Lizzie222 (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More